Nuwacell Biotech

Nuwacell Biotech is a clinical-stage biotechnology company headquartered in Hefei, China, specializing in the development of induced pluripotent stem cell (iPSC) derived therapies. The company focuses on creating standardized, off-the-shelf cell products to treat a variety of degenerative and incurable diseases, including Parkinson's disease and heart failure. Nuwacell's lead program, NCC-001, is an iPSC-derived dopaminergic neuron precursor therapy that has entered clinical trials for the treatment of Parkinson's disease. By leveraging its proprietary iPSC technology and large-scale GMP manufacturing capabilities, the company aims to provide scalable and affordable regenerative medicine solutions. Nuwacell is supported by prominent investors and maintains a robust pipeline targeting neurology, cardiology, and ophthalmology.